樂觀
$4.04
情境價格
$22.490
-0.252 (-1.12%)收盤時
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Latest Wall Street Rating Updates

Latest Wall Street Ratings and Price Target Adjustments

Fortrea Grants Stock Awards to New Employees

Fortrea Acquires Early Phase Services Division, Stock Rises

Fortrea Acquires Worldwide's Early Phase Services for $45 Million
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。